CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer

2018111 citationsJournal Articlegold Open Access

Authors

Jennifer Pasquier · Cornell University

Marie Gosset · Hôpital Lariboisière

Caroline Geyl · Inserm

Jessica Hoarau-Véchot · Weill Cornell Medical College in Qatar

A Chevrot · Inserm

Marc Pocard · Hôpital Lariboisière

Massoud Mirshahi ·

Abstract

These findings highlight the potential key role of the stroma in protecting minimal residual disease from chemotherapy, thus favoring recurrences. Future clinical trials targeting stroma could use anti-IL-6 therapy in association with chemotherapy.

Topics & Keywords

Ovarian cancer diagnosis and treatment Cancer Cells and Metastasis Reproductive Biology and Fertility

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Molecular Cancer

Volume 17, Issue 1, pp. 47-47

DOI: 10.1186/s12943-018-0787-z

Field-Weighted Citation Impact: 10.46